AI Article Synopsis
- Molecular endoscopy is advancing from research to clinical trials in the study of inflammatory bowel disease (IBD).
- In-vivo studies using fluorescent antibodies are focusing on crucial areas like targeted therapy distribution, treatment modes of action, and predicting patient responses.
- This technology has the potential to personalize IBD treatment by using molecular data to tailor therapies for individual patients.
Article Abstract
Molecular endoscopy in inflammatory bowel disease (IBD) has made the translation from preclinical studies to clinical trials. The so far performed in vivo studies, using fluorescent antibodies, have addressed areas of heightened clinical interest with unmet needs. These include the distribution of targeted therapies within the mucosa, which could elucidate the most fitting dosing for the individual patient, the mode of action of currently used treatments, and subsequently also the prediction of therapeutic response. Altogether, molecular endoscopy might enable us to base individualized therapeutic decisions on preceded in vivo molecular analysis to optimize treatment in IBD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.giec.2024.09.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!